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Abstract
Background/Aims: Cystic Fibrosis (CF) is an inherited disease associated with a variety of 
mutations affecting the CFTR gene. A deletion of phenylalanine 508 (F508) affects more than 
70% of patients and results in unfolded proteins accumulation, originating a proteinopathy 
responsible for inflammation, impaired trafficking, altered metabolism, cholesterol and lipids 
accumulation, impaired autophagy at the cellular level. Lung inflammation has been extensively 
related to the accumulation of the lipotoxin ceramide. We recently proved that inhibition of 
ceramide synthesis by Myriocin reduces inflammation and ameliorates the defence response 
against pathogens infection, which is downregulated in CF. Here, we aim at demonstrating the 
mechanisms of Myriocin therapeutic effects in Cystic Fibrosis broncho-epithelial cells. Methods: 
The effect of Myriocin treatment, on F508-CFTR bronchial epithelial cell line IB3-1 cells, was 
studied by evaluating the expression of key proteins and genes involved in autophagy and 
lipid metabolism, by western blotting and real time PCR. Moreover, the amount of glycerol-
phospholipids, triglycerides, and cholesterols, sphingomyelins and ceramides were measured 
in treated and untreated cells by LC-MS. Finally, Sptlc1 was transiently silenced and the 
effect on ceramide content, autophagy and transcriptional activities was evaluated as above 
mentioned. Results: We demonstrate that Myriocin tightly regulates metabolic function and 
cell resilience to stress. Myriocin moves a transcriptional program that activates TFEB, major 
lipid metabolism and autophagy regulator, and FOXOs, central lipid metabolism and anti-
inflammatory/anti-oxidant regulators. The activity of these transcriptional factors is associated 
with the induction of PPARs nuclear receptors activity, whose targets are genes involved in lipid 
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transport compartmentalization and oxidation. Transient silencing of SPTCL1 recapitulates the 
effects induced by Myriocin. Conclusion: Cystic Fibrosis bronchial epithelia accumulate lipids, 
exacerbating inflammation. Myriocin administration: i) activates the transcriptions of genes 
involved in enhancing autophagy-mediated stress clearance; ii) reduces the content of several 
lipid species and, at the same time, iii) enhances mitochondrial lipid oxidation. Silencing the 
expression of Sptlc1 reproduces Myriocin induced autophagy and transcriptional activities, 
demonstrating that the inhibition of sphingolipid synthesis drives a transcriptional program 
aimed at addressing cell metabolism towards lipid oxidation and at exploiting autophagy 
mediated clearance of stress. We speculate that regulating sphingolipid de novo synthesis 
can relieve from chronic inflammation, improving energy supply and anti-oxidant responses, 
indicating an innovative therapeutic strategy for CF.
Introduction
Cystic fibrosis (CF) is a hereditary disease related to six different classes of mutations, 
affecting the chloride/carbonate channel CFTR [1]. CFTR dysfunction has a devastating effect 
primarily on the lungs and pancreas physiology and function. Although CF causes life threat 
because of pulmonary inflammation and infections, the improved therapeutic management 
of the last decades significantly increased life expectancy up to late adulthood.  The disease, 
along with aging, is characterized by chronic inflammation and progressive manifestation and 
deterioration of comorbidities. Among comorbidities, dyslipidemia with high triglycerides 
and low LDL and cholesterol levels were identified in plasma of CF patients [2, 3], together 
with peripheral tissue fat accumulation [2, 4-8]. CF-related malabsorption of cholesterol 
is thought to enhance its synthesis, thus contributing to cholesterol accumulation, in the 
liver but also in other tissues [9, 10]. The most common CF mutations belong to class II 
and include the 508-phenylalanine deletion, which is encoded in 70% of mutant alleles in 
Caucasian patients. This mutation originates a proteinopathy due to DF508-CFTR unfolded 
protein accumulation, which saturates the clearance ability of the ER-associated degradation 
(ERAD), even when enhanced by the UPR system [11, 12]. The UPR modulates the expression 
of a variety of genes, that are involved in ER-related activities such as proteasome-lysosomal 
degradation, protein synthesis, sphingo- and glycerol-lipids and cholesterols metabolism, 
efficaciously adapting cell activities to a survival response to stress [13, 14]. Aggregates 
accrual, formed by misfolded mutant CFTR and a miscellaneous of sequestered proteins 
within, induces inflammation and oxidative stress, impairing proteins and lipids transport 
[1, 15]. Autophagy is a major supportive harm evoked under stress conditions and aimed to 
the degradation of unnecessary or un-wanted materials. Due to such aggregate-formation 
prone phenotype of DF508-CFTR expressing cells, autophagy is impaired by the segregation 
and degradation of key autophagic proteins, thus exacerbating the proteinopathy induced 
stress [12]. Intracellular organized lipid storages are a source for autophagosome membrane 
formation [16]. Consequently, an upregulated lipid synthesis or deregulated transport and 
metabolism was demonstrated to impair autophagy and to trigger ER stress [16-18]. TFEB 
is a master regulator of stress response insuring energy refueling via autophagy induction 
and lipid oxidation [19]. Autophagy sustains the clearance of proteins, lipids (lipophagy) 
[20] and infective pathogens (xenophagy) [21, 22]. A TFEB target is p62-sequestosome, a 
key component of autophagy vesicles that  connects TFEB activation to lipophagy, in support 
of mitochondrial b-oxidation of fatty acids; interestingly, p62-sequestosome loss is also 
associated with diabetes and obesity [23]. Moreover, TFEB activates a set of genes involved 
in lipid mobilization and oxidation, mostly by the induction of the transcriptional activities 
of PPARs, their co-activator PGC-1α and FOXOs [20, 24].
FOXOs and PPARs transcriptional activity regulates lipid metabolism and inflammatory 
reaction. CF epithelial cells have reduced the level of FOXO1 [25], and CF models have a 
profound deficiency in the function of the lipid-activated PPAR-g [26], possibly due to 
its sequestration into aggregates [27]. Overall, these observations suggest that protein 
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misfolding in the ER leads to global effects on lipid homeostasis [28]. Importantly, such 
cellular deregulation of lipid homeostasis is somewhat mirrored in CF patients by altered 
plasma lipid profile [3, 8, 9, 29-33]. Cholesterol increased synthesis was associated to DF508-
CFTR expression, independently from CFTR channel function, but caused by late endosomal/
lipid vesicle traffic impairment, in response to the proteinopathy stress. Moreover, the 
accumulation of esterified cholesterol in endosomal vesicles is accompanied by defects in the 
traffic of glycosphingolipids [7, 10, 34, 35]. These outcomes recall the Niemann-Pick disease 
type C (NPC) deficiency of cholesterol transport [36], responsible for membrane equilibrium 
alteration and impaired lipid trafficking [7]. The altered cholesterol transport and metabolism 
are sensed by the ER leading to the activation of SREBP (sterol regulatory element-binding 
protein) and endogenous cholesterol synthesis, in CFTR deficient cells [7] and mice [37]. 
Accordingly, CF patients present increased cholesterol in the lung and trachea sections [38]. 
Sphingomyelin, phosphatidylcholine, and cholesterol are the major components of cellular 
membranes. Their synthesis occurs at ER and it requires the coordinated activity of all the 
involved enzymes insuring that the modulation of one lipid class is related to the modulation 
of the other two classes [39], following  the overall design of feeding the membranes [40-43]. 
Thus, triggering cholesterol synthesis may cause an increased synthesis of sphingolipids 
[14, 44]. Sphingolipid and glycerolipid metabolisms overlap at the enzymatic step where 
ceramide competes with diacylglycerol for the phosphocholine (deriving from CDP-choline). 
The ratio between the key enzymes of the two pathways, Serine Palmitoyl Transferase over 
Glycerol 3-phosphate Acyl Transferase, is significantly higher in the microsomal lung (and 
pancreas) than in most other adult rat tissues; accordingly, the percentage of sphingomyelin 
is higher in the total phospholipid content in these fractions [45, 46]. Sphingomyelin is 
formed, at Golgi or plasma membrane, by the addition of phosphocholine to ceramide. 
Ceramide is the core molecule of all sphingolipids metabolites, synthesized in the ER and 
translocated by vesicles or protein-mediated transport to the Golgi apparatus. Ceramide 
accumulation is involved in a variety of proteinopathies, that share with CF an inflammatory 
and ER stress condition, due to altered proteostasis, such as Retinitis Pigmentosa, 
Parkinson’s, Alzheimer’s, and Hungtinton’s diseases [47, 48]. We and others previously 
demonstrated that ceramide content is pathologically increased in CF lungs and pulmonary 
epithelia, and that pharmacological impairment of ceramide accumulation reduces chronic 
inflammation and bacterial/fungal infections in CF [49-54]. Gulbins and his research group 
demonstrated that ceramide increases in CF lungs via enhanced sphingomyelin hydrolysis 
and they evaluated, in a clinical trial, the therapeutic effect of the sphingomyelinase 
inhibitor amitriptyline, a tricyclic antidepressant, which is already known for its action on 
lipid membranes and related signaling in neuropharmacology [49]. We proved, in different 
models, that de novo sphingolipid synthesis is an inflammation responsive pathway. It is 
enhanced by inflammatory mediators, both at transcriptional and at enzyme activity level 
and the accumulation of its metabolite ceramide potentiates inflammation in a vicious circle 
[52, 53, 55]. In this manuscript, we provide evidences that Myriocin (Myr), by inhibiting 
the first and rate-limiting reaction in the sphingolipid de novo synthesis pathway, is able to 
promote lipid oxidation and overall reduction and to induce autophagy, thus driving energy 
fueling and stress removal in DF508-CFTR bronchial epithelial cells.
Materials and Methods
Reagents and antibodies
The following materials were purchased: LHC Basal, LHC-8 w/o gentamicin culture media from Gibco 
(US); Fetal Bovine Serum and Minimum Essential Medium Earle’s salt from EuroClone Life Science Italy; 
penicillin/streptomycin and RIPA buffer were purchased from Sigma-Aldrich; OA/BSA cell colture mix 
(Sigma); protease inhibitors cocktail (Roche); Quick Start™ Bradford Dye Reagent and Clarity™ Western 
ECL Blotting Substrates, iScriptTM cDNA synthesis, retro-transcription  kit (BioRad); BODIPY 493/503 (4, 
4-difluoro-1, 3,5, 7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene), catalogue number D3922, and BODIPY™ 
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558/568 C
12
 (4, 4-Difluoro-5-(2-Thienyl)-4-Bora-3a,4a-Diaza-s-Indacene-3-Dodecanoic Acid), catalogue 
number D3835, Prolong® Gold antifade reagent, were purchased from ThermoFisher Scientific, Molecular 
Probes™; NE-PER™ Nuclear and Cytoplasmic Extraction Reagents from ThermoFisher Scientific; ReliaPrep™ 
Miniprep RNA extraction System and GoTaq qPCR Master Mix (Promega); SYBR Green system (Qiagen); 
synthetic oligonucleotides from M-Medical Italy. The chemicals acetonitrile (ACN), 2-propanol (IPA), 
methanol, chloroform, formic acid (FA) and ammonium formate were purchased by Sigma-Aldrich (Milan, 
Italy). Cholesterol d7 (cod. 700041P), C15 ceramide d7 (cod. 860681P), 15:0-18:1-d7-phosphatidylcholine 
(cod. 791637C) and 16:0-18:0-16:0 d5 triglyceride (cod. 860902P), used as internal standards were 
purchased by Avanti Polar Lipids (Alabaster, AL). All aqueous solutions were prepared using purified water 
at a Milli-Q grade (Millipore, Milan, Italy). Primary antibodies: anti- PPAR-g, Foxo1A and anti-Laminin A/C 
(ElabScience, US), SQSTM1/p62 (D1Q5S), anti b-actin (Sigma, US), anti-TFEB (ab2636, Abcam), anti-LC3 
(Cell Signaling, US). The secondary antibodies were purchased from Jackson Laboratories (Bar Harbor, ME, 
US).
Cell lines and treatments
IB3-1 cells (named CF cells), an adeno-associated virus-transformed human bronchial epithelial cell 
line derived from a CF patient (DF508/W1282X) and provided by LGC Promochem (US), were grown in 
LHC-8 medium supplemented with 10% FBS, 1% penicillin/streptomycin at 37°C and 5% CO
2
. Human lung 
bronchial epithelial cells 16HBE14o- (named healthy), originally developed by Dieter C. Gruenert, were 
provided by Luis J. Galietta, (Telethon Institute of Genetics and Medicine - TIGEM, Napoli) and cultured, 
as recommended, in Minimum Essential Medium (MEM) Earle’s salt, supplemented with 10% FBS, 1% 
penicillin/streptomycin at 37°C and 5% CO
2
. Myriocin (Myr) treatments were performed at a concentration 
of 50 µM, for the indicated time lengths, in 100 mm dishes plated at 1x105 cells/each.
Protein extraction and western blotting
For transcriptional factors western blottings, nuclear and cytoplasmic extracts from cells were 
obtained with the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (ThermoFisher Scientific) 
according to the manufacturer’s instructions. Total cell proteins were extracted from cells in RIPA buffer. 
The concentration of proteins in lysates was measured by Quick Start™ Bradford Dye Reagent (595 nm OD 
read). 50mg of proteins per sample were separated on SDS-PAGE gel and electro-blotted onto an either PVDF 
membrane for LC3 protein detection or nitrocellulose membrane for other protein targets. After washing in 
Tris-buffered saline containing 0.1% Tween-20 (TBS-T) and blocking with 5% non-fat dry milk for 1 hour 
at room temperature, membranes were probed overnight at 4°C with the primary antibodies. After three 
washes in TBS-T, the blot was incubated with the horseradish peroxidase-conjugated secondary antibodies. 
After the final washings, proteins were detected using an enhanced chemo-luminescent horseradish 
peroxidase substrate and the relative bands were captured and quantified by Alliance UVITEC Cambridge.
qRT-PCR
Cells were harvested, washed in PBS and total RNA was isolated from cell pellet with the ReliaPrep™ 
Miniprep RNA extraction System, according to the manufacturer’s instructions. 1 mg of purified RNA was 
reverse transcribed and the obtained cDNA was stored at -20°C. The amplification of target genes was 
performed for the following targets: TFEB (TFEB), LAMP 2a, 2b and 2c (LAMP2a,2b,2c), PGC-1a (PPARGC1A), 
PPAR-a (PPARA), PPAR-g (PPARG), FOXO 1a and 3a (FOXO 1a, 3a), FATP1 (SLC27A1), CPT-1a (CPT1A), CPT-
1b (CPT1B), SCAD (ACADS), MCAD (ACADM), LCAD (ACADL). Relative mRNA expression of target genes 
was normalized to the endogenous GAPDH control gene and represented as fold change versus control, 
calculated by the comparative CT method (∆∆CT Method). All the primer sequences are reported in the 
Supplementary Table 1 (for all supplemental material see www.cellphysiolbiochem.com).
Lipidomic analysis
Lipids extraction from cell pellets was performed using a monophasic extraction method with water: 
chloroform: methanol (1:3:6 v/v/v) [56]. Then a small aliquot (2 µl) of the extracts was analysed by LC-
HRMS (Shimadzu UPLC coupled with a Triple Tof 6600 Sciex). All samples were analysed in duplicate in 
positive mode with electrospray ionization for the identification and semi-quantification of sphingolipids, 
cholesterol and its esters, phospholipids and triacylglycerols. MS/MS spectra were acquired by data 
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dependent acquisition. Separation was achieved by an Acquity BEH C18 column 1.7 μm 2.1x50 mm (Waters, 
MA, USA) using as mobile phase A water/acetonitrile (60:40) and as mobile phase B 2-propanol/acetonitrile 
(90:10) both containing 10 mM ammonium formate and 0.1% of formic acid. The identification and semi-
quantification were attained using MS-DIAL (ver. 3.82) [57]. Peak intensities of each lipid were normalized 
(Intensity norm.) by correcting for both total amount of protein (mg) measured by Bradford method and 
total-ion count. Results were presented as the sum of the normalized intensity for each lipid within a class. 
Absolute sphingolipid determination was achieved using a targeted analysis by a LC-MS/MS system (Dionex 
3000 UltiMate coupled to a tandem mass spectrometer AB Sciex 3200 QTRAP) as already described [58].
Sptlc1 silencing by siRNA
CF cells were seeded in 6 wells plates and grown for 24 hours (70% confluency). For each well, 20pmol 
of Sptlc1 siRNA (or Scrambled sequence as negative control, Thermofisher) were diluted into 250 μl of Opti-
MEM (w/o FCS); 5ul of Lipofectamine RNAiMAX (Thermofisher) was diluted into 250 μl of Opti-MEM LHC8 
(w/o FCS); diluted oligomers and lipofectamine were gently mixed and incubated at RT for 15 minutes, 
then added to each cell colture well in a total volume of 2ml/well of serum free medium (LHC8). Cells were 
incubated at 37°C in a CO2 incubator for 5 hours, than fresh medium, containing 10% FCS, was replaced, 
either with or without 30 μM of oleic acid/BSA. Cells were additionally incubated up to 24-48 hours before 
collecting for analytical procedures.
Statistical analysis
All the experiments were performed in a minimum of 3 separate experiments. In some cases, the 
reported data derive from 5 independent experiments. Data are expressed as mean ± SD, calculated from 
experimental replicates. For western blotting analysis, the images are the most representative whereas 
the quantification of protein signals is calculated on the average of all the experiments performed.  Data 
significance was evaluated by two-tailed Student T-test or ANOVA test followed by Bonferroni post test 
(p<0.05), as indicated in figure legends. Statistical analysis was performed by GraphPad Instat software (La 
Jolla, CA, USA) and graph illustrations generated by GraphPad Prism software (La Jolla, CA, USA).
Results
Myriocin induces autophagy in CF epithelial cells
Proteinopathies, in particular, DF508CFTR induced CF, are characterized by impaired 
cellular transports, ER stress, and deficiency in proteasomal and autophagic clearance of 
accumulated material. Therefore, we evaluated the effect of Myr treatment on autophagy 
induction in DF508CFTR and in a healthy broncho epithelial cell line as control. CF cells 
exhibit a reduced basal amount of lipidated form of LC3 (LC3II) in respect to healthy broncho 
epithelial cells (Fig. 1 A and B), as previously shown [12]. We demonstrated that Myr (50 
mM) was effectively inducing the accumulation of the lipidated form of LC3 (LC3II) within 5 
hours of treatment (Fig. 1A). In addition, we observed that Myr (50 mM) induced a significant 
reduction of p62-sequestosome in CF cells (Fig. 1B). These observations indicate that the 
treatment with Myr induced an increase in autophagic flux in CF cells.
Myriocin induces TFEB, PPARγ and FOXO1A nuclear translocation in CF epithelial cells
In order to understand why Myr is able to enhance autophagy, we investigated the 
activation of TFEB, a key inducer of autophagy and a regulator of energy homeostasis. TFEB 
nuclear migration and activation is significantly increased in CF cells treated with Myr (50 mM) 
versus untreated cells, already after 5 hours of treatment (Fig. 2A). By promoting autophagy, 
TFEB enhances lipid catabolism at the aim of conveying cell resources to energy production 
and to organize a survival stress response. To do so, TFEB promotes the activation of PPARs 
and FOXOs family of transcriptional factors involved in lipid homeostasis and inflammatory 
responses. We demonstrated that a slightly longer treatment with Myr (50 mM, 12 hours) 
stimulates nuclear translocation of PPAR-g and FOXO1A (Fig. 2A, 2B).
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Myriocin activates a stress response transcriptional program
TFEB is a master regulator of the transcription of genes involved in autophagy and 
lysosome formation. First of all, the same TFEB expression resulted increased upon Myr 
treatment (50 mM, 12 hours; Fig. 3A) in CF cells versus healthy cells, indicating that initial 
activation of this critical regulatory factor is sustained, in the time, by the activation of a 
transcriptional program underlining TFEB induced effect. Next, we evaluated the expression 
of Myr nuclear translocation-activated transcriptional factors PPARγ and FOXO1A. We 
observed that their activation is sustained by their increased expression (Fig. 3B, 3E), 
together with the increased expression of PPAR-a, PGC1a and FOXO3A (Fig. 3C, 3D, 3F). 
Therefore, Myr drives the expression of a set of genes that are aimed at sustaining lipid 
catabolism and energy production inhibition. To note that Myr induced transcriptional 
activities is significantly regulated in CF cells but only to a minor extent in healthy cells. 
Fig. 1. Myriocin induces autophagy in CF cells. CF cells and healthy cells, treated with Myriocin for 12 hours. 
Detection of LC3 I and II protein expression by western blot in absence or in presence of 1 hour treatment 
with chloroquine and normalized on β-actin (A). Quantification of LC3II/I ratio obtained from triplicate 
samples and normalized onto β Actin and represented in the bars graph.  Quantification of P62 protein 
expression by western blot analysis on whole lysates and normalized on β-actin (B); two-tailed unpaired 
Student’s T-test.
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Figure 1
Fig. 2. Myriocin induces transcriptional factors activation. CF bronchoepithelial cells were treated or not with 
Myr (5 hours for TFEB evaluation and 12 hours for PPARγ; C, FOXO1A). Quantification of the transcriptional 
factor nuclear translocation by western blot on nuclear extracts and normalized on Lamin A/C: A, TFEB; 
B, PPARγ; C, FOXO1A. Protein signals were quantified by densitometry analysis and the normalized values 
reported in the graphs; two-tailed unpaired Student’s T-test.
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Then, we evaluated the expression of TFEB targets, involved in sustain of autophagy flux, 
Lamp2a, Lamp2b, and Lamp2c. We observed that overnight (24 hours) treatment with Myr 
(50 mM) increased the expression of all these genes in CF cells versus healthy cells (Fig. 4A). 
In order to verify the effect of PPARs and FOXOs activation, we evaluated the expression of 
their target genes involved in lipid transport and catabolism. We proved that a 24 hours Myr 
treatment significantly increases the expression of the plasma membrane lipid transporter 
FATP1 (Slcl27a1), which mediates the uptake of long-chain FA, and the expression of the 
transporters Ctp1a and Cpt1b, which instead control the mitochondrial entry of FA for 
oxidation, as compared to untreated cells (Fig. 4B and 4C). In order to prove that fat entry 
and mobilization was finalized at oxidation and energy production, we evaluated the Myr-
induced transcriptional response of enzymes involved in mitochondrial fatty acid oxidation 
(FAO). SCAD (ACADS), MCAD (ACADM) and LCAD (ACADL), which are the mitochondrial 
dehydrogenases primarily responsible for b-oxidation of small, medium and long chains of 
FAs respectively, are upregulated by 24 hours Myr treatment, reaching statistical significance 
for ACADL (Fig. 4C). To note that Myr significantly upregulated the transcription of the above 
mentioned genes in CF cells but only to a minor extent in healthy cells.
Fig. 3. Myriocin activates the transcription of TFEB-induced transcriptional factors. Quantification of the 
expression of genes encoding for transcriptional factors activated by TFEB: A, TFEB; B, Ppar-g; C, Ppar-a;D, 
Pgc1a; E, Foxo1A; F, Foxo3A by qRT-PCR, in CF cells and healthy cells, treated and untreated with Myr (12 
hours). All data are normalized on the housekeeping gene GAPDH and expressed as mean±SE (* p<0.05; ** 
p<0.01; *** p<0.001); two-tailed unpaired Student’s T-test. Figure 3
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Myriocin reduces lipid content in CF epithelial cells
Myr inhibits ceramide and related sphingolipids synthesis and, according to our 
results, it also promotes the expression of genes involved in lipid oxidation. We compared 
the amount of different lipid species in Myr treated healthy and CF cells, versus untreated 
ones. CF cells have a significantly higher content in sphingolipids (namely ceramides CER 
and sphingomyelins SM), glycerophospholipids (namely phosphatidylcholine PC and 
phosphatidylserine, PS), triacylglycerols (TAG) and cholesterol esters (CE) (Fig. 5 A, B, C, 
E, H, I). We observed that Myr not only reduces ceramide and sphingomyelin content (Fig. 
5A-4C), but it also reduces glycerolipids (PC, PS and phosphatidylethanolamine, PE), Lyso-
phosphatidylcholine (LPC), TAG, and cholesterol esters (CE), with a particular significance 
for the decrease of PC, PS, and CE (Fig. 5). Thus, the inhibition of sphingolipids biosynthesis 
causes an overall depletion of cellular lipids from different classes.
Fig. 4. Myriocin activates the 
transcription of TFEB-induced 
autophagy and lipid metabolism 
related genes in CF and healthy 
broncho epithelial cells. 
Quantification of the expression of 
genes involved in autophagy and 
cell lipid transport/metabolism: A, 
Lamp alternative splicing derived 
mRNA levels (Lamp2a, Lamp2b, 
Lamp2c);B, Fatp1; C, CPT1a, 
CPT1b and; D, AcadL, AcadM and 
AcadS  by qRT-PCR in CF cells and 
healthy cells, treated and untreated 
with Myr (24 hours). All data are 
expressed as mean±SE (* p<0.05; 
** p<0.01; *** p<0.001; **** 
p<0.0001); two-tailed unpaired 
Student’s T-test for Fig. 4B and 
Anova followed by Bonferroni 
post-test for all other Figures.
Figure 4
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Fig. 5. LCMS measurement 
of different lipid species and 
Myriocin effects in CF cells and 
in healthy (H) broncho epithelial 
cells. The content of different lipid 
species was analyzed by LC-MS. 
CF cells lipid content is higher 
than healthy in all the observed 
species; 24 hours Myr reduced the 
content of all the evaluated lipid 
species in CF cells: A, Ceramide 
(Cer); B, Sphingomyelin (SM); 
C, phosphatidylcholine (PC); D, 
phosphatidylethanolamine (PE); 
E, phosphatidylserine (PS); F, 
Lysophosphatidylcholine (LPC); 
G, lysophosphatidylethanolamine 
(LPE); H, triacylglycerols (TE); 
I, cholesterol esters (CE); L, 
free cholesterols (CF). Data are 
expressed as mean ± SE (* p<0.05; 
** p<0.01); Anova followed by 
Bonferroni post-test.
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Reduced expression of SPT1 recapitulates Myr effects
To better prove that the control of sphingolipid synthesis is tightly linked to the overall 
cell metabolism and it can be used to switch on stress response and total lipid consume 
in CF model, we transiently silenced the expression of Sptlc1 gene, by specific targeting of 
its mRNA, siRNA, in CF cells. We observed a reduction of 83% gene expression within 24 
hours, that was still stable at 48 hours (Fig. 6A), paralleled by a reduced protein expression 
of more than 50% (6B). After 48 hours, Cer and SM were significantly reduced, indicating 
the efficacy of gene expression silencing in counteracting sphingolipid de novo synthesis 
(Fig. 6C and D). In order to prove that Sptlc1 downregulation reproduces the effects of Myr 
treatment, we evaluated the induction of autophagy by LC3 lipidation analysis via western 
blotting. We observed that Sptlc1 silencing significantly enhances autophagic flux, either in 
the presence or in the absence of chloroquine for lysosomal activity inhibition (24 hours). 
Since nucleotide oligomers may activate autophagy, we added scrambled siRNA as a control, 
showing a slight and not significant increase of LC3II/LC3I ratio in respect to control (w/o 
scrambled siRNA) (Fig. 6E). Next, we compared the expression of the key genes activated 
by Myr in Sptlc1-silenced cells versus control. We investigated the expression of TFEB, 
master regulator of autophagy and energy metabolism, and we observed that 24 hours 
Sptlc1-silenced CF cells exhibit an increased expression of TFEB (Fig. 6F), and of one of its 
target genes involved in autophagic flux, LAMP2a (Fig. 6H). Similarly to Myr, Sptlc1 silencing 
increased the expression of PPARα (Fig. 6G), CPT1a (Fig. 6I), involved in fatty acids entry into 
mitochondria, and of ACADs (Fig. 6L), the dehydrogenases involved in fatty acids β oxidation 
(especially the enzyme which preferentially recognizes long chain fatty acids). From these 
data we conclude that the effects of Myr are entirely due to its inhibitory activity on SPT 
enzyme and that reducing the synthesis of sphingolipids triggers the TFEB mediated stress 
response of autophagy and lipid consume.
Discussion
We previously showed the therapeutic potential of Myr, a fungal-derived molecule 
known to be a specific inhibitor of the Serine Palmitoyl Transferase, rate-limiting enzyme 
of the sphingolipid synthesis. We proved that intra-trachea administration of this molecule 
reduces chronic inflammation and ameliorates endogenous rejection of bacterial and fungal 
infections in CF murine models [52, 53]. We also demonstrated that Myr corrects the defective 
ability of CF epithelial cells to kill internalized pathogens [53]. We here investigated the 
mechanisms underlying the therapeutic actions of Myr. CF proteinopathy is characterized 
by defective autophagy response to stress and altered lipid metabolism, as previously 
elucidated. In this manuscript, we demonstrate that Myr treatment of DF508CFTR broncho-
epithelial cells is able to recover and stimulate autophagy, leading to LC3II accumulation 
and p62-sequestosome consume, thus counteracting the CF defective mechanism. In order 
to understand how an inhibitor of the sphingolipids’ synthesis can be related to autophagy 
induction, we investigated the activation of TFEB, one of the master regulator of stress 
response. TFEB activation allows energy gain from the oxidation of lipid storage and the 
recycle of dispensable material via autophagy, inducing, at the same time, anti-oxidant 
response and sustaining mitochondrial activity [24, 59]. In doing so, TFEB stimulates the 
activation of other transcriptional factors such as PPARs and FOXOs, which regulate the lipid 
oxidation and the anti-inflammatory response [22, 24, 60, 61] We previously demonstrated 
that Myr induces TFEB transcriptional activation and its down stream pathway which is aimed 
at enhancing lipid oxidation and ATP production in myocardium [62]. We here observed 
that Myr promotes TFEB nuclear translocation and, subsequently, the nuclear translocation 
of PPAR-g and Foxo1A, demonstrating that a transcriptional program is triggered by this 
molecule, aimed at enhancing cellular energy metabolism and reducing inflammation. In 
line with the activation of these transcriptional factors, we previously showed that Myr 
significantly reduces inflammatory cytokines transcription and release and favours the anti-
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oxidant response by inducing the HO-1 transcription in DF508CFTR CF epithelial cells [53]. We 
now demonstrate that the transcription of genes involved in lipid transport (cellular import 
and mitochondrial import of FA) and their mitochondrial oxidation (FA dehydrogenases), 
known to be stimulated by the TFEB/PPARs-axis, are significantly increased, indicating that, 
effectively, Myr enhances lipid consume. Consequently, we performed a lipidomic analysis 
of CF cells and healthy cells treated with Myr and observed an overall increased content of 
Fig. 6. Transient silencing of Sptlc1 
expression recapitulates Myr 
effects in CF cells. A) Quantification 
of the expression of the gene 
encoding for Sptlc1 was obtained 
by qRT-PCR in CF cells treated with 
Sptlc1-directed siRNA for 24 and 
48 hours. All data are normalized 
on the housekeeping gene GAPDH 
and expressed as mean±SE (* 
p<0.05; ** p<0.01; *** p<0.001); 
two-tailed unpaired Student’s T-
test. B). Detection of SPT1 protein 
expression by western blotting 
in cells treated with Sptlc1-
directed siRNA for 24 hours. LCMS 
quantification of Ceramides (C) and 
Sphingomyelins (D) in cells treated 
with Sptlc1-directed siRNA for 48 
hours. E) Detection of LC3 I and 
II protein expression by western 
blot, in absence or in presence of 1 
hour treatment with chloroquine. 
Quantification of LC3II/I ratio 
obtained from triplicate samples 
of Sptlc1-siRNA or Scrambled-
siRNa or vehicle was normalized 
onto β Actin and represented in 
the bars graph. Quantification 
by qRT-PCR of the expression of 
genes encoding for transcriptional 
factors activated by TFEB after 24 
hours of Sptlc1 directed siRNA: F), 
TFEB; G), Ppar-a; quantification by 
qRT-PCR of the expression of genes 
encoding for TFEB- induced genes 
after 24 hours of Sptlc1 directed 
siRNA: H) Lamp2a; I) Cpt1a; L) 
AcadL, AcadM, AcadS. All data are 
normalized on the housekeeping 
gene GAPDH and expressed as 
mean±SE (* p<0.05; ** p<0.01; 
*** p<0.001); Anova followed by 
Bonferroni post-test for Fig. L and 
two-tailed unpaired Student’s T-
test for the other Figures.
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glycerophospholipids, sphingolipids and cholesterols in CF cells versus healthy cells. To the 
best of our knowledge, this is the first report of increased lipids content in CF pulmonary 
epithelia and it is in line with reported cholesterol accumulation in peripheral tissues in 
CF patients. Lipids accumulation can derive from impaired membrane trafficking, and it is 
responsible for clogging the ER-Golgi network, exacerbating ROS and inflammation in CF. 
Lipids content was significantly reduced by Myr treatment in CF. The reduction is particularly 
evident for phosphatidylcholine and cholesterol esters. Moreover, lyso- glycerophospholipids, 
considered pro-inflammatory molecules [63, 64], were significantly reduced, indicating a 
decreased inflammation-driven metabolism of the lipid moiety. To note, healthy cells were 
poorly affected, indicating that Myr is acting on a CF specific defective mechanisms of lipid 
altered homeostasis.
Conclusion
Thus, lipids homeostasis is intrinsically deranged in DF508CFTR proteinopathy of CF, 
and lipid metabolism stands for an important therapeutic target that can be envisaged in 
sustain of pharmacological efficiency of correctors. Based on our results, we can envision that 
Myr treatment has the potential of partially restoring CF cellular dysmetabolism, releasing 
cells from the excessive stress which is deemed an important cause of correctors failure in 
CF patients. We can also speculate that this molecule may exert favourable systemic effects 
to reduce dyslipidemia occurring in CF patients. The limitation in this present study is the 
overall difference between a CF cell line and a patient’s derived broncho epithelium. We are 
aware that molecular signaling might be affected by peculiarities of the specific cell line and 
this is the reason why we intend to investigate the mechanism of Myr induced autophagy 
and relief from proteinopathy stress, as well as lipid accumulation in CF primary cells. The 
comparison between primary broncho epithelial cells derived from CF patients and from 
control donors will furtherly shed light on lipid dysmetabolism in CF.
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